Mereo BioPharma (MREO) Net Cash Flow (2023 - 2026)

Mereo BioPharma (MREO) has 4 years of Net Cash Flow data on file, last reported at -$4.6 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$4.6 million, up 43.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$27.0 million (down 306.83% YoY), and the FY2025 annual result was -$30.7 million, down 343.09% from the prior year.
• Net Cash Flow advanced to -$4.6 million in Q1 2026 per MREO's latest filing, from -$7.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $38.9 million in Q2 2024 and troughed at -$9.7 million in Q1 2023.
• A 4-year average of -$2.8 million and a median of -$7.8 million in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 601.39% in 2024 and fell as far as 176.79% in 2024.
• A 4-year view of Net Cash Flow shows it stood at -$6.8 million in 2023, then slumped by 39.34% to -$9.5 million in 2024, then increased by 19.21% to -$7.6 million in 2025, then surged by 39.66% to -$4.6 million in 2026.
• Business Quant data shows MREO's Net Cash Flow at -$4.6 million in Q1 2026, -$7.6 million in Q4 2025, and -$7.0 million in Q3 2025.